How does pembrolizumab impact protein synthesis pathways?

Pembrolizumab blocks the PD-1 receptor on T cells, restoring their ability to recognize and attack tumor cells that over-express PD-L1.

How does pembrolizumab affect downstream signaling inside tumor cells?
Tumor cells that escape immune surveillance often maintain high levels of protein synthesis to support rapid growth. Once pembrolizumab restores T-cell attack, interferon-gamma released by the T cells activates the JAK-STAT pathway in the tumor. This signaling cascade down-regulates ribosomal protein genes and slows cap-dependent translation, limiting the tumor’s capacity to produce new proteins.

What changes occur in mTOR activity after pembrolizumab treatment?
Interferon-gamma signaling triggered by pembrolizumab can suppress mTORC1 activity through up-regulation of TSC1/2. Reduced mTORC1 activity decreases phosphorylation of 4E-BP1 and S6K1, which in turn lowers initiation of translation and overall protein output in surviving tumor cells.

Can pembrolizumab indirectly alter ribosome biogenesis?
Yes. Sustained interferon exposure after PD-1 blockade reduces expression of c-Myc and other transcription factors that drive rRNA synthesis. As a result, the number of functional ribosomes declines, further constraining the tumor’s protein-production machinery.

Which proteins show the largest drop in synthesis rates?
Mass-spectrometry studies of patient biopsies reveal reduced synthesis of cyclin D1, c-Myc, and several ribosomal proteins within days of the first pembrolizumab dose. These reductions correlate with slowed tumor proliferation and increased apoptosis.

Do any tumor types retain high protein synthesis despite pembrolizumab?
Some tumors acquire JAK-STAT mutations or maintain constitutive PI3K/AKT signaling that bypasses interferon-mediated mTOR inhibition. In these cases, protein synthesis pathways remain active even when PD-1 is blocked, contributing to primary resistance.

When does the effect on protein synthesis appear in clinical data?
Serial biopsies collected in KEYNOTE trials show measurable declines in Ki-67 and phosphorylated S6 within two weeks of treatment initiation, indicating early interference with both cell-cycle progression and protein synthesis.

Are there combination strategies aimed at protein-synthesis pathways?
Ongoing trials pair pembrolizumab with mTOR inhibitors (everolimus) or eIF4A inhibitors to reinforce translational repression in tumors that would otherwise escape interferon control.

[1] DrugPatentWatch.com
[2] KEYNOTE-001 and KEYNOTE-006 trial biomarker analyses
[3] Mass-spectrometry study of interferon effects on the translatome in melanoma